IP Library Granted Patent US 8,663,931
Granted Patent B2
US 8,663,931 · App. 13/266,411 · Granted Mar 4, 2014

Method for detecting renal disease comprising measuring human megalin in urine

Inventors: Akihiko Saito (Niigata, JP); Yasuhiko Tomino (Bunkyo-ku, JP); Katsuhiko Asanuma (Bunkyo-ku, JP); Shinya Ogasawara (Gosen, JP); Hiroyuki Kurosawa (Gosen, JP); Yoshiaki Hirayama (Gosen, JP)
Assignees: Niigata University; Juntendo Educational Foundation; Denka Seiken Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,663,931
App. No.
13/266,411
Granted
Mar 4, 2014
Kind
B2
Abstract

This invention provides a diagnostic kit and a diagnostic marker used for diagnosing a renal disease. This invention also provides a method for detecting a renal disease comprising measuring at least one type of human megalin existing in urine selected from among full-length human megalin and human megalin fragments of (i) to (iii): (i) full-length human megalin; (ii) a human megalin endodomain fragment lacking a human megalin ectodomain; and (iii) a human megalin ectodomain fragment lacking a human megalin endodomain.

Claims (11)

1. A method for treating a subject suffering from a renal disease, comprising:

(i) comparing an amount of human megalin ectodomain fragment measured in a urine sample of the subject to that of healthy individuals; and

(ii) directing treatment of the subject pursuant to a prognosis based on said comparing, wherein

(A) a higher amount of human megalin ectodomain fragment in the urine sample indicates a poor prognosis and

(B) the renal disease is selected from the group consisting of diabetic nephropathy, IgA nephropathy, nephritic syndrome, lupus glomerulonephritis, Henoch-Schonlein purpura nephritis, crescentic glomerulonephritis.

2. A method for treating a subject at risk of advancement of renal disease, comprising:

(i) determining that the subject's excretion level in urine for human megalin ectodomain fragment exceeds normal levels of excretion for said fragment, such that the subject is identified as having a high risk of renal disease advancement; and, on the basis of such identification,

(ii) causing the subject to undergo preventive treatment;

wherein the renal disease-associated with tubular dysfunction is selected from the group consisting of diabetic nephropathy, IgA nephropathy, nephritic syndrome, lupus glomerulonephritis, Henoch-Schonlein purpura nephritis, crescentic glomerulonephritis.

3. The method for detecting a renal disease according to claim 1 , wherein the human megalin ectodomain fragment in the urine sample has an amino acid sequence corresponding to amino acids 26 to 4361, amino acids 26 to 314, or amino acids 4362-4437 of SEQ ID NO. 2.

4. The method for detecting a renal disease according to claim 2 , wherein the human megalin ectodomain fragment in the urine sample has an amino acid sequence corresponding to amino acids 26 to 4361, amino acids 26 to 314, or amino acids 4362-4437 of SEQ ID NO. 2.

Assignments (2)
MERGER Recorded Oct 5, 2020
From: DENKA SEIKEN CO., LTD.
To: DENKA COMPANY LIMITED
Reel/Frame 053976/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2011
From: SAITO, AKIHIKO; TOMINO, YASUHIKO; ASANUMA, KATSUHIKO; OGASAWARA, SHINYA; KUROSAWA, HIROYUKI; HIRAYAMA, YOSHIAKI
To: NIIGATA UNIVERSITY; JUNTENDO EDUCATIONAL FOUNDATION; DENKA SEIKEN CO., LTD.
Reel/Frame 027127/0426 →
Priority Claims (1)
JP 2009-108498 · Apr 27, 2009 · national
Continuity (1)
Related Publication 20120040374A1 · Feb 16, 2012